Analysts predict that Vascular Biogenics (NASDAQ:VBLT) will post earnings of ($0.17) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Vascular Biogenics’ earnings. Vascular Biogenics posted earnings per share of ($0.18) during the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The company is expected to announce its next earnings results on Monday, August 13th.
On average, analysts expect that Vascular Biogenics will report full year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.72). For the next financial year, analysts anticipate that the firm will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.77) to ($0.74). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Vascular Biogenics.
Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Thursday, May 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). The company had revenue of $0.16 million for the quarter.
Several research firms recently weighed in on VBLT. ValuEngine cut shares of Vascular Biogenics from a “sell” rating to a “strong sell” rating in a research note on Friday, March 9th. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Saturday. Piper Jaffray Companies cut shares of Vascular Biogenics from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Thursday, March 8th. Chardan Capital cut shares of Vascular Biogenics from a “buy” rating to a “neutral” rating and cut their target price for the company from $25.00 to $3.00 in a research note on Thursday, March 8th. Finally, HC Wainwright set a $3.00 target price on shares of Vascular Biogenics and gave the company a “hold” rating in a research note on Thursday, March 22nd. Two analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. The stock has an average rating of “Hold” and an average target price of $3.19.
Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc lifted its position in Vascular Biogenics by 339.7% during the fourth quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 15,117 shares during the last quarter. Alps Advisors Inc. bought a new position in Vascular Biogenics during the fourth quarter valued at $234,000. ARK Investment Management LLC bought a new position in Vascular Biogenics during the fourth quarter valued at $302,000. Finally, Raymond James & Associates lifted its position in Vascular Biogenics by 71.5% during the fourth quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after purchasing an additional 23,124 shares during the last quarter. Institutional investors and hedge funds own 5.49% of the company’s stock.
Vascular Biogenics remained flat at $$2.20 during trading on Tuesday, according to MarketBeat. 32,490 shares of the company traded hands, compared to its average volume of 78,479. The stock has a market capitalization of $65.77 million, a PE ratio of -5.95 and a beta of -1.69. Vascular Biogenics has a 52 week low of $2.01 and a 52 week high of $9.05.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Get a free copy of the Zacks research report on Vascular Biogenics (VBLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.